Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

HUTCHMED (US: HCM)

Last close As at 21/11/2024

31.59

▲ −2.99 (−8.65%)

Market capitalisation

5,463m

Edison Investment Research is terminating coverage on HUTCHMED. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare | ADR Update

Hutchison China MediTech — A rolling stone gathers no moss

Healthcare | Update

Hutchison China MediTech — A rolling stone gathers no moss

Healthcare | ADR Update

Hutchison China MediTech — To China and beyond

Healthcare | Update

Hutchison China MediTech — To China and beyond
Visit Website

Sector

Healthcare

Share Price Performance

Financials

Edison Investment Research is terminating coverage on HUTCHMED. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Update

Healthcare

Hutchison China MediTech — Elunate receives China NRDL inclusion

Update

Healthcare

Hutchison China MediTech — Elunate receives China NRDL inclusion

Update

Healthcare

Hutchison China MediTech — Surufatinib NETs solid data at ESMO

Update

Healthcare

Hutchison China MediTech — Surufatinib NETs solid data at ESMO

ADR Update

Healthcare

Hutchison China MediTech — Onwards and upwards

Update

Healthcare

Hutchison China MediTech — Onwards and upwards

Outlook

Healthcare

Hutchison China MediTech — An emerging global biopharma

Outlook

Healthcare

Hutchison China MediTech — An emerging global biopharma

Update

Healthcare

Hutchison China MediTech — Fruquintinib capsules approved in China

Update

Healthcare

Hutchison China MediTech — Establishing a global operational presence

Update

Healthcare

Hutchison China MediTech — Establishing a global operational presence

Outlook

Healthcare

Hutchison China MediTech — Jewels in the crown

ADR Update

Healthcare

Hutchison China MediTech — WCLC highlights savolitinib combination potential

Update

Healthcare

Hutchison China MediTech — WCLC highlights savolitinib combination potential

Update

Healthcare

Hutchison China MediTech — ASCO data set up fruquintinib for China launch

ADR Outlook

Healthcare

Hutchison China MediTech — Future stars are aligning

Outlook

Healthcare

Hutchison China MediTech — Future stars are aligning

ADR Update

Healthcare

Hutchison China MediTech — Update 28 February 2017

Update

Healthcare

Hutchison China MediTech — Update 27 February 2017

Outlook

Healthcare

Hutchison China MediTech — Update 12 December 2016

Outlook

Healthcare

Hutchison China MediTech — Update 9 December 2016

ADR Outlook

Healthcare

Hutchison China MediTech — Update 27 May 2016

Outlook

Healthcare

Hutchison China MediTech — Update 27 May 2016